These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 38916311)

  • 1. Construction and immunogenicity of SARS-CoV-2 virus-like particle expressed by recombinant baculovirus BacMam.
    Nguyen HT; Falzarano D; Gerdts V; Liu Q
    Microbiol Spectr; 2024 Aug; 12(8):e0095924. PubMed ID: 38916311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development, production and characterization of SARS-CoV-2 virus-like particles (Coronaviridae:
    Latyshev OE; Zaykova ON; Eliseeva OV; Savochkina TE; Chernoryzh YY; Syroeshkin AV; Petrov GV; Vorkunova GK; Larichev VF; Fediakina IT; Cherepushkin SA; Tsibezov VV; Yuzhakova KA; Kulikova NY; Lebedeva VV; Yakunin DY; Kozlova AA; Baranets MS; Yurlov KI; Lesnova EI; Grebennikova TV
    Vopr Virusol; 2024 May; 69(2):175-186. PubMed ID: 38843023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
    Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
    Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of human post-vaccination SARS-CoV-2 standard reference sera.
    Xiang J; Katz L; Winokur PL; Chaudhary A; Digmann B; Bradford R; Rashid S; Ghosh S; Robertson A; Menetski J; Xu M; Gao P; Chen CZ; Lee T; Poelaert B; Eastman RT; Hall MD; Stapleton JT
    J Immunol Methods; 2024 Jul; 530():113698. PubMed ID: 38823574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.
    Wang G; Verma AK; Guan X; Bu F; Odle AE; Li F; Liu B; Perlman S; Du L
    J Virol; 2024 Sep; 98(9):e0037624. PubMed ID: 39189731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioproduction and immunogenic evaluation of SARS-CoV-2 prototype vaccine in silkworm BmN cells.
    Zheng H; Zhao H; Xiong H; Awais MM; Zeng S; Sun J
    Int J Biol Macromol; 2024 Sep; 276(Pt 2):134027. PubMed ID: 39033889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Integrated Platform for Serological Detection and Vaccination of COVID-19.
    Wei SC; Hsu WT; Chiu CH; Chang FY; Lo HR; Liao CY; Yang HI; Chou YC; Tsai CH; Chao YC
    Front Immunol; 2021; 12():771011. PubMed ID: 35003088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats.
    Tcheou J; Raskin A; Singh G; Kawabata H; Bielak D; Sun W; González-Domínguez I; Sather DN; García-Sastre A; Palese P; Krammer F; Carreño JM
    Front Immunol; 2021; 12():791764. PubMed ID: 34868082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
    Brunet J; Choucha Z; Gransagne M; Tabbal H; Ku M-W; Buchrieser J; Fernandes P; Batalie D; Lopez J; Ma L; Dufour E; Simon E; Hardy D; Petres S; Guinet F; Strick-Marchand H; Monot M; Charneau P; Majlessi L; Duprex WP; Gerke C; Martin A; Escriou N
    J Virol; 2024 May; 98(5):e0169323. PubMed ID: 38563763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudotyping Improves the Yield of Functional SARS-CoV-2 Virus-like Particles (VLPs) as Tools for Vaccine and Therapeutic Development.
    Zak AJ; Hoang T; Yee CM; Rizvi SM; Prabhu P; Wen F
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2024; 15():1420304. PubMed ID: 39267752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
    van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
    Front Immunol; 2021; 12():781280. PubMed ID: 34987509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.
    Ying B; Liang C-Y; Desai P; Scheaffer SM; Elbashir SM; Edwards DK; Thackray LB; Diamond MS
    J Virol; 2024 Sep; 98(9):e0057424. PubMed ID: 39194250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study.
    Tang R; Zeng Y; Zhou Y; Liang Q; Kang W; Yang Z; Zheng X; Zang X; Pan H; Jin J; Zhu F
    Expert Rev Vaccines; 2024; 23(1):498-509. PubMed ID: 38695310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
    Nambulli S; Escriou N; Rennick LJ; Demers MJ; Tilston-Lunel NL; McElroy AK; Barbeau DJ; Crossland NA; Hoehl RM; Schrauf S; White AG; Borish HJ; Tomko JA; Frye LJ; Scanga CA; Flynn JL; Martin A; Gerke C; Hartman AL; Duprex WP
    J Virol; 2024 May; 98(5):e0176223. PubMed ID: 38563762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins.
    Chen J; Xu W; Li L; Yi L; Jiang Y; Hao P; Xu Z; Zou W; Li P; Gao Z; Tian M; Jin N; Ren L; Li C
    Front Cell Infect Microbiol; 2022; 12():967493. PubMed ID: 35923799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.
    Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D
    Front Immunol; 2021; 12():719077. PubMed ID: 34394127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.